as on October 18, 2025 at 1:29 am IST
Day's Low
Day's High
1.64%
Downside
2.63%
Upside
52 Week's Low
52 Week's High
57.26%
Downside
53.92%
Upside
Check Bicara Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.0B
EPS (TTM)
-2.2213
Dividend Yield
0.00%
PE Ratio (TTM)
0PEG Ratio
0Return On Equity TTM
64638800.00%
Compare market cap, revenue, PE, and other key metrics of Bicara Therapeutics with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
NA | $1.0B | NA | NA | 0.00% | |
BUY | $63.1B | 231.27% | -505.15 | -12.96% | |
NA | $36.7B | NA | NA | -3.89% | |
BUY | $104.8B | 91.13% | 29.04 | 31.86% | |
BUY | $60.3B | -3.62% | 14.35 | 31.37% |
The Bicara Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Bicara Therapeutics investment value today
Current value as on today
₹87,900
Returns
Returns from Bicara Therapeutics Stock
Dollar Returns*
₹4,794 (+4.79%)
Search interest for Bicara Therapeutics Stock has increased by 1450% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:1450% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
In the last 1 month, BCAX stock has moved up by 74.8%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.8% return, outperforming this stock by 79.7%
Organisation | Bicara Therapeutics |
Headquarters | 116 Huntington Avenue, Boston, MA, United States, 02116 |
CEO | Dr. Claire Mazumdar Clemon M.B.A., Ph.D. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Ryan Cohlhepp Pharm.D. | President, COO & Director |
Ms. Lara S. Meisner J.D. | Chief Legal Officer & Corporate Secretary |
Ms. Angela Windt | VP & Head of Regulatory Affairs |
Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs |
Mr. Jean-Paul Rodrique | Senior VP & Global Head of Quality Assurance |
Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | CEO & Director |
Mr. Ivan Hyep M.B.A. | Chief Financial Officer |
Ms. Rachel Salazar | SVP of R&D Strategy and Operations |
Ms. Sathish Hasige Ph.D. | Senior VP and Head of Technical Operations & Supply Chain |
Dr. David Raben M.D. | Chief Medical Officer |
Bicara Therapeutics share price today is $18.25 as on at the close of the market. Bicara Therapeutics share today touched a day high of $18.73 and a low of $17.95.
Bicara Therapeutics share touched a 52 week high of $28.09 on and a 52 week low of $7.8 on . Bicara Therapeutics stock price today i.e. is closed at $18.25,which is 35.03% down from its 52 week high and 133.97% up from its 52 week low.
Bicara Therapeutics market capitalisation is $0.00T as on .
Indian investors can start investing in Bicara Therapeutics (BCAX) shares with as little as ₹87.954 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹879.54 in Bicara Therapeutics stock (as per the Rupee-Dollar exchange rate as on ).
Based on Bicara Therapeutics share’s latest price of $18.25 as on October 18, 2025 at 1:29 am IST, you will get 0.5479 shares of Bicara Therapeutics. Learn more about
fractional shares .